NeuBase Therapeutics Analysis
NeuBase Therapeutics is undervalued with Real Value of 0.0 and Hype Value of 0.0. The main objective of NeuBase Therapeutics delisted stock analysis is to determine its intrinsic value, which is an estimate of what NeuBase Therapeutics is worth, separate from its market price. There are two main types of NeuBase Therapeutics' stock analysis: fundamental analysis and technical analysis.
The NeuBase Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and NeuBase Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
NeuBase |
NeuBase Stock Analysis Notes
About 13.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.18. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. NeuBase Therapeutics recorded a loss per share of 18.6. The entity last dividend was issued on the 4th of February 2019. The firm had 1:20 split on the 15th of June 2023. NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania. Neu Base operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 33 people. To find out more about NeuBase Therapeutics contact Dietrich Stephan at 412 763 3350 or learn more at https://www.neubasetherapeutics.com.NeuBase Therapeutics Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more delisted stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. NeuBase Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding NeuBase Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| NeuBase Therapeutics is not yet fully synchronised with the market data | |
| NeuBase Therapeutics has some characteristics of a very speculative penny stock | |
| NeuBase Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (33.78 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| NeuBase Therapeutics currently holds about 29.85 M in cash with (29.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.93. | |
| Roughly 13.0% of the company outstanding shares are owned by corporate insiders |
NeuBase Therapeutics Upcoming and Recent Events
| 13th of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 30th of September 2023 Last Quarter Report | View |
NeuBase Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 1.42 M.NeuBase Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific NeuBase Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on NeuBase Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases NeuBase Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
NeuBase Therapeutics Outstanding Bonds
NeuBase Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. NeuBase Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most NeuBase bonds can be classified according to their maturity, which is the date when NeuBase Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding NeuBase Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Stocks Directory Now
Stocks DirectoryFind actively traded stocks across global markets |
| All Next | Launch Module |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Other Consideration for investing in NeuBase Stock
If you are still planning to invest in NeuBase Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the NeuBase Therapeutics' history and understand the potential risks before investing.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |